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NOTES AND COMMENTS 
living in the ‘post-antibiotic era’: could the use of 
probiotics be an effective strategy? 
The progressive increase in bacterial antibiotic resistance 
has reached such a degree that there is now talk of ‘the 
end of the antibiotic era’ 111. While new chemical 
entities that act Qrectly on pathogens, such as the 
oxazolidinones [2] and everninomicin [3], and a variety 
of Merent types of peptide antibiotics [4,5] are very 
welcome and may provide a short-term solution, this 
stereotyped response is not the answer to the overall 
problem. It is clear that other strategies to combat the 
spread and effects of microbial resistance are needed. 
To address this problem, we must, like the roman 
god Janus, look both forward and backward at the same 
time. Thus, new ideas include novel targets in the 
bacterial cell, e.g. teichoic acid [6] and the pentaglycine 
bridge in staphylococci [7], and blocking microbial 
receptor sites on the eucaryotic cell with oligo- 
saccharides [S]. In the hture, antibiotics may be 
administered together with a chaperone that actually 
prevents resistance emerging by blocking its mechanism 
(e.g. by inhibiting antibiotic efflux pumps, or by 
preventing the biosynthesis of PBP2’) [9]. Old ideas 
such as developing new vaccines for protective and 
therapeutic purposes [lo], and better control of in- 
fection measures, are also increasingly recognized as 
capable of contributing greatly to the problem of tack- 
ling infectious disease in the twenty-first century. 
Another old idea is the use of probiotics. Increasing 
public understanding of science and medicine over the 
past decades means that it is now generally recognized 
that not all ‘germs’ are harmful, as a previous generation 
had been brought up to believe. Commensal flora can 
protect &om the invasion of pathogens, and it is only a 
short step h m  t h i s  to the concept that modulation of 
the bowel flora by the deliberate ingestion of ‘fiiendly’ 
bacteria will maintain health. 
A connection between the quality and quantity of 
life and the state of the intestines has existed since 
Hippocrates wrote in c. 400 BC ‘death sits in the 
bowels; a bad digestion is the root of all evil’. The 
German physician Hufeland advocated in 1853 a 
‘macrobiotic’ diet (the word translates literally fiom the 
Greek as ‘long Me’). However, it was the Russian 
microbiologist Metchnikoff who popularized at the 
beginning of the twentieth century the notion that the 
wrong sort of resident flora in the intestines might be 
exterting a detrimental long-term effect upon health. 
So strongly did he believe thls that he suggested 
resecting portions of the large intestine, thereby 
reducing its bacterial load, in order to prolong life ill]. 
Less drastically, he also recommended the Bulgarian 
practice of drinking fermented milk, and, in particular, 
yoghurt, as a Me-lengthening habit. It is hardly sur- 
prising that of Metchnikoffs two suggestions, nutrition 
proved more popular than surgery. 
Probiotic bacteria include the anaerobes that pro- 
vide the gut with colonization resistance [12] and 
in particular the bacteria that produce lactic acid, 
especially lactobacilli and bifidobacteria. Probiotic 
bacteria are available in the form of supplements (often 
called ‘Acidophdus’) , bioyoghurts and fermented milks. 
Friendly bacteria already in the gut may be encouraged 
by the ingestion of substrates that they, but neither 
the host nor the unfiiendly bacteria, can utilize. Such 
substrates (usually oligosaccharides) are called prebiotics. 
A combination of prebiotics and probiotics is called a 
synbiotic. 
It is not only bacteria that have probiotic pro- 
perties. Saccharomyces boulardii has been used in man 
[13], and S. cerevisiae and Aspergillus oryzae (among 
others) in ruminants 1141. 
Probiotics are widely used, as shown by the large 
number of different brands of supplements available, 
and respectable, being retaded not only in health food 
shops but also in pharmacies. They are recommended 
by some health workers for specific comphnts, and are 
advertized in general terms as aids to a healthy lifestyle. 
Thus, here is an inexpensive, non-antibiotic 
potential therapeutic and prophylactic intervention 
already in place and acceptable to the public. Are 
probiotics safe and effective, how do they work and 
how broad should their application be? 
Probiotic bacteria are chosen to have suitable 
characteristics, e.g. of human origin, resistant to bile 
and acid, adhering to human cells, antagonistic to ‘un- 
friendly' bacteria (by production of hydrogen peroxide, 
bacteriocins, etc.) and having immunomodulating 
properties [l5]. The species most commonly used are 
Lactobacillus acidophilus, L. rhamnosus, Bijidobactetium 
bijidum and Enterocoms faecium. The first two of these 
are only rarely pathogens, and a recent survey in 
Finland [16] has failed to establish any association 
between human disease and probiotic organisms. B .  
bijidum is not known to be a pathogen. E. jheciurn, on 
the other hand, is an organism probably best avoided 
as a probiotic, in view of its ability to acquire resistance 
and also to cause infection in the immunocom- 
promized [17]. 
2 
N o t e s  a n d  Comments 3 
There are a limited number of controlled trials 
concerning specific clinical entities in which various 
probiotic preparations have been shown to have a 
beneficial therapeutic or prophylactic effect. These 
have been reviewed [15,18-261. Most ofthe conditions 
involved the gastro-intestinal or uro-genital tracts. 
There are also trials (and there may be other, un- 
published studies) showing probiotics to have no effect. 
Many of the trials can be criticized, as often undefined 
probiotic strains were used, no attempts made to 
establish optimal dosage regimens in terms of microbial 
load or length of treatment, and few contain adequate 
microbiological investigations. Use of probiotics for the 
condition called ‘dysbiosis’, allegedly due to an im- 
balance of intestinal flora, which apparently manifests 
as irritable or inflammatory bowel disease, chronic 
constipation or chronic fatigue syndrome, or for many 
other indications for which conventional medicine has 
so far failed to provide a cure, is supported only by 
anecdotal evidence. 
The use of probiotics in humans at present still 
comes into the category of ‘alternative medicine’, 
and its progression must be planned with this in mind. 
The mainstream medical profession is now developing 
a more enlightened attitude. A recent Editorial in 
a leading U.S. medical journal [27] urges medical 
practitioners to be open-minded, encourages them to 
perform proper studies on new therapies, not to 
ridicule or ignore the potential of the placebo effect, 
not to accept new therapies as efficacious on first 
acquaintance, and to avoid arrogant and hubristic 
attitudes. Those who believe that probiotics may be an 
alternative to antibiotics should now press on with 
carefully designed, properly carried out randomized 
trials using well-defined strains of probiotics, and 
publish results in peer-reviewed journals. The cost, in 
terms of time, energy and cash, may be considerable, 
but the rewards should outweigh this. Moves currently 
under way in the U.S.A. to clarfi the status of ‘nutra- 
ceuticals’ with respect to Drug Regulatory Authorities 
[28] should encourage suppliers of probiotics to fund 
such trials. 
J M. T Hamilton-Miller 
Department of Medical Microbiology, 
Royal Free Hospital School of Medicine, 
Pond Street, 
London NW3 2QG, UK 
References 
1. Neu HC. The crisis in antibiotic resistance. Science 1992; 
2. Brickner SJ, Hutchison DK, Barbachyn M R ,  Manninen 
PR, Ulanowicz DA, Garmon SA, et al. Synthesis and 
257: 1064-1073. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
antibacterial activity of U-100592 and U-100766, two 
oxazolidinone antibacterial agents for the potential treatment 
of multi-drug resistant Gram-positive bacterial infections. 
J Med Chem 1996; 39: 673-679. 
Nakashio S, Iwasawa H, Dun Ey, Kanemitsu K, Shimida J. 
Everninomicin, a new oligosaccharide antibiotic: its anti- 
microbial activity, post-antibiotic effect and synergistic 
bactericidal activity. Drugs Expel Clin Res 1995; 21: 7-16. 
Stachelhaus T, Schneider A, Marahiel MA. Engineered 
biosynthesis of peptide antibiotics. Biochem Pharmacol 
Hancock REW, Falla TJ. Antimicrobial peptides: broad- 
spectrum antibiotics h m  nature. Clin Microbiol Inf 1996; 
Canepari P, Boaretti M. Lipoteichoic acid as a target for 
antimicrobial action. Microb Drug Res 1996; 2: 85-89. 
Kopp U, Roos M, Wecke J, Labischinksi H. Staphylococcal 
peptidoglycan interpeptide bridge biosynthesis: a novel 
antistaphylococcal target? Microb Drug Res 1996; 2: 29-41. 
Zopf D, Roth S. Oligosaccharide anti-infective agents. 
Lancet 1996; 347: 1017-1021. 
Chin J. Resistance is useless. New Scient 1996; 152 (Oct 12): 
Grange JM, Stanford JL. Therapeutic vaccines. J Med 
Microbiol 1996; 45: 81-83. 
Bibel DJ. Elie Metchnikoffs bacillus of long life. ASM News 
Vollaard EJ, Claesner HAL. Colonization resistance. Anti- 
microb Agents Chemother 1994; 38: 409-414. 
McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, 
Moyer KA, Melcher SA et al. Prevention of B-lactam- 
associated diarrhea by Sarrharomyces boulardii compared with 
placebo. h e r  J Gastroenterol 1995; 90: 439-448. 
Wallace RJ, Newbold CM. Microbial feed additives for 
ruminants. In Fuller R et al. eds. Probiotics: Prospects of Use 
in Opportunistic Infections, Institute for Microbiology and 
Biochemistry, Herborn Dill. 1995: 101-125. 
Lee Y-K, Salminen S. The coming of age of probiotics. 
Trends Fd Sci Techno1 1995; 6: 241-245. 
Saxelin M, Chuang N-H, Chassy B, Rautelin H, Makela 
PH, Salminen S et al. Lactobacilli and bacteremia in 
Southern Finland, 1989-1992. Clin InfDis 1996; 22: 564- 
566. 
Jett BD, Huycke MM, Gilmore MS. Virulence of entero- 
1996; 52: 177-186. 
1: 226-229. 
32-35. 
1988; 54: 661-665. 
cocci. Clin Microbiol Rev 1994; 7: 462-478. 
18. Reid G, Bruce AW, McGroarty JA, Cheng K-J, Costerton 
LW. Is there a role for lactobacilli in prevention of urogenital 
and intestinal infections? Clin Microbiol Rev 1990; 3: 
335-344. 
19. Fuller R. Probiotics in human medicine. Gut 1991; 32: 
439-442. 
20. Goldin BR, Gorbach SL. Probiotics for humans. In Fuller 
R .  ed. Probiotics, The Scientific Basis. London: Chapman 
21. McGroarty JA. Probiotic use of lactobacilli in the human 
female urogenital tract. FEMS Immunol Med Microbiol 
22. Bergogne-Berezin E. Impact ecologique de l’antibio- 
& Hall, 1992: 355-376. 
1993; 6: 251-264. 
therapie. Presse Med 1995; 24: 145-156. 
4 Clinical Microbio logy and Infection, Volume 3 Number  1, February  1997 
23. Tannock GW. Role of probiotics In Gibson GR ed. Human 
Colonic Bacteria: Role in Nutrition. Boca Raton: CRC 
PXSS, 1995: 257-271 
24. Rusch VC, Zimmerman K. Microbial therapy with 
Enterocouus faecalk and Escherichia coli: experimental and 
clinical dam. In Fuller R et al, eds. Probiotics: Prospects of 
Use in Opportunistic Infections. Institute of Microbiology 
and Biochemistry, Herborn-Dill 1995 158-172. 
25. Araneo BA, Cebra JJ, Beuth J, Fuller R ,  Heidt PJ, Midvedt 
T et al. Problems and priorities for controlling opportunistic 
pathogens with new antimicrobial strategies; an overview of 
current literature. Z Bakt 1996; 283: 431-465. 
26. Hamilton-Miller JMT. Probiotics -panacea or nostrum? 
BNF Nutrit Bull 1996; 21: 199-208. 
27. Alpert JS. The relativity of alternative medicine. Arch Int 
Med 1995; 155: 2385. 
28. Barnett AA. Nutraceuticals seek credibility in USA. Lancet 
1996; 347: 1397. 
Scedosporium species: the rising importance of newly 
emerging fungal pathogens 
Scedosporium refers to a family of fungi which cause 
infections s d a r  in te rm of diversity and severity 
to those caused by Aspergillus, and mycetomas. Two 
species of Scedosporium are medically sigtllficant: Scedo- 
sporium apiospermum (first identified in 1909 b m  a 
mycetoma) and Scedosporium pro l f iam (isolated &om a 
bone biopsy in 1984). 
These pathogens are more fiequently detected, and 
only their isolation in culture confirms the diagnosis; 
other methods are not reliable. The low sensitivity of 
the fungus to presently available antifUngal agents 
account for the serious prognosis of such infections. 
Epidemiology 
Scedospon'um species are saprophpc agents isolated b m  
many natural substrates (soils, potted plants, polluted 
water). The geographic distribution of mycetomas 
shows a predomination in temperate and sub-tropical 
areas. Other types of infections have been observed 
worldwide [ 11. 
To conform to taxonomists' recommendations, the 
name of the sexual state Pseudalleschetia boydii has to be 
preferentially used rather than Scedosporium apiospermum 
(but no sexual state has been discovered for Scedospon'um 
prollficans). 
Clinical manifestations 
Clinical aspects differ according to the species, the 
route of contamination and the immune status of the 
host (Table 1). 
Table 1 Clinical aspects of Scedosporium infections 
Scedosporium Sudosporium 
apiospenum (l? boydii) prollficanr 
Through direct Mycetoma (presence Localized infections 
inoculation of white grains) +++ (osteomyelitis++) 
Localized infections 
Through Simple pulmonary Simple pulmonary 
inhalation colonization colonization 
Allergic broncho- Invasive pulmonary 
pulmonary disease disease (and metastatic 
Inwive pulmonary lesions) 
disease (and metastatic 
lesions] 
Scedosporium apiospemum (Pseudallescheria boydii) 
In t h s  case, direct inoculations (through a trauma 
wound or a wound puncture) are reported, causing 
mycetomas (cutaneous and subcutaneous lesions pro- 
ducing white grains). 
To a lesser degree, localized infections are described 
(orbit, cutaneous and subcutaneous tissues, brain, 
joints, bone): they are usually called pseudallescheriasis 
(not mycetoma) because of the lack of grains [2]. 
Mycetomas and localized infections are observed in 
previously normal hosts, but the latter may also be 
observed during metastatic dissemination of the fungus 
during an invasive process. 
Aerial contamination may lead to invasive pul- 
monary disease in immunosuppressed patients, often 
followed by spread to other areas of the body because 
of the angioinvasive nature of the fungus [3]. Invasive 
disease with l? boydii is described in the normal host, 
following submersion in polluted water. 
A simple endobronchal or pulmonary coloniza- 
tion may be seen in adults over 40 years of age with 
pre-existing disease (such as bronchiectasis or tuber- 
culosis), and in farmers. These cases of colonization are 
difficult to differentiate fiom lung invasion. Allergic 
bronchopulmonary disease due to I? boydii has been 
described in patients with asthma or previous allergic 
bronchopulmonary aspergdlosis. 
Scedosporium pmlificans 
Almost all infections with S. prolificam followed a 
penetrating trauma wound and remain localized [4]. 
It usually causes osteomyelitis, but other sites may be 
infected. Disseminated infections have been described 
in neutropenic patients. Although rare, an increasing 
number of such cases have been observed. 
Little is known about the host factors control- 
ling immunity in the course of scedosporiosis, but 
